Clinically, ALCL with ALK gene fusion displays extremely aggressive tumor phenotypes but paradoxically, these patients have noticeably better prognosis than those without ALK fusion (with 71% vs. 15% of patients surviving over 10 years) [29]. The gene discussed is ALK; the disease is neoplasm.